REG - Indivior PLC - Dr. David Wheadon appointed Chair of the Board

IndiviorAnnouncement

28/01/2025 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250128:nRSb0023Va&default-theme=true

RNS Number : 0023V  Indivior PLC  28 January 2025

Indivior PLC

Dr. David Wheadon appointed Chair of the Board

Richmond, VA, January 28, 2025 - The Board of Directors of Indivior PLC are
pleased to announce the appointment of Dr. David Wheadon as Chair of the Board
with immediate effect. Dr. Wheadon joined the Board as a Non-Executive
Director in June 2024.  His appointment was approved by the Board, following
a succession process undertaken by the Nomination Committee and led by Juliet
Thompson, Lead Independent Director.

Separately, and further to the announcement of December 17, 2024, the Board is
working with Oaktree Capital Management LP to identify and appoint an
additional Non-Executive Director to the Board, which it expects to announce
shortly.

Previous to joining the Indivior Board, Dr. Wheadon served as senior vice
president of global regulatory affairs, patient safety, and quality assurance
at AstraZeneca Plc from December 2014 to July 2019. Prior to that, he was
executive vice president, research and advocacy at Juvenile Diabetes Research
Foundation International Inc., from May 2013 to December 2014, and senior vice
president, scientific and regulatory affairs at Pharmaceutical Research and
Manufacturers of America (PhRMA), from January 2009 to May 2013. Prior to that
he served as vice president, global pharmaceutical regulatory and medical
science, and group vice president, global pharmaceutical regulatory affairs at
Abbott Laboratories from 2005 to 2009 and held senior regulatory and clinical
development leadership positions at GlaxoSmithKline Plc and Eli Lilly and
Company.

Dr. Wheadon received his M.D. from Johns Hopkins University School of Medicine
and an A.B. in Biology from Harvard University.  He completed his
postdoctoral training in Psychiatry at Tufts/New England Medical Center in
Boston, Massachusetts.

Dr. Wheadon is a Non-Executive Independent Director of Sotera Health Company
and Vaxart, Inc. He also serves as a member of the Board of Trustees of Mount
Sinai Health System.

Dr. Wheadon is currently a member of the Compensation, Nomination, and Science
Committees. Dr. Wheadon has also been appointed Chair of the Nomination
Committee.

Comment by Juliet Thompson, Lead Independent Director

I am delighted to announce David's appointment as Chair of the Board and am
confident he will bring strong leadership to the role, leveraging his track
record across specialty pharma and beyond.  David has already established
himself as a valued member of the Board and we look forward to benefitting
from his continued insights and deep strategic and operational experience as
we work together to deliver value to all Indivior stakeholders.

Comment by Dr. David Wheadon, Chair of the Board of Indivior PLC

It is an honor to become Chair of the Board of Indivior. This is a great
company which is unwavering in its mission to help change patients' lives by
pioneering life-transforming treatment for opioid use disorder. I am very
proud to be appointed to lead the Board and support that mission.

I look forward to working closely with the Board and management team to
leverage Indivior's deep expertise, long track record and strong culture. As a
Board, we are determined to help realize the Company's great potential and
deliver value for shareholders and our wider stakeholders.

About Indivior

 

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat substance use disorders (SUD). Our
vision is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and co-occurring disorders
of SUD. Indivior is dedicated to transforming SUD from a global human crisis
to a recognized and treated chronic disease. Building on its global portfolio
of OUD treatments, Indivior has a pipeline of product candidates designed to
expand on its heritage in this category. Headquartered in the
United States in Richmond, VA, Indivior employs over 1,000 individuals
globally and its portfolio of products is available in over 30 countries
worldwide. Visit www.indivior.com
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.indivior.com%2F&data=05%7C02%7Cdavid.wisniewski%40Indivior.com%7C46151793371f4a5a147b08dced4812d0%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C638646141028285945%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=vwwjBavEG8GHlzYIHaEEC6eKfaZlLZYEsM1w5sIS1B8%3D&reserved=0)
 to learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior
(https://nam12.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Findivior&data=05%7C02%7Cdavid.wisniewski%40Indivior.com%7C46151793371f4a5a147b08dced4812d0%7Cbed52191489442999db948e4fb29646e%7C1%7C0%7C638646141028306668%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=mWdLO9fvlp1vQv6%2F30I2DGhuwyieW3W262QTgrk4ZVQ%3D&reserved=0)
.

 

Investor Enquiries:

 

Jason Thompson

VP, Investor Relations

Indivior PLC

+1 804 402 7123

jason.thompson@indivior.com

 

Tim Owens

Director, Investor Relations Indivior PLC

+1 804 263 3978

timothy.owens@indivior.com

 

Media Enquiries:

 

For Indivior:

 

Jonathan Sibun

Teneo

+44 (0)20 7353 4200

Indiviormediacontacts@indivior.com (mailto:Indiviormediacontacts@indivior.com)

 

Tim Lynch / Maggie Carangelo

Joele Frank, Wilkinson Brimmer Katcher

+1 212 895 8600

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPPUACGUPAGCR